Last reviewed · How we verify
NCT05734378: PRO-SVD
Prognosis of Cerebral Small Vessel Disease
trial in Cerebral Amyloid Angiopathy in 900 participants. Currently enrolling.
30 November 2030
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 900 |
| Start date | 1 December 2020 |
| Primary completion | 30 November 2030 |
| Estimated completion | 30 November 2030 |
| Sites | 1 location across Switzerland |
Conditions studied
- Cerebral Amyloid Angiopathy — all drugs for Cerebral Amyloid Angiopathy →
- Small Vessel Cerebrovascular Disease — all drugs for Small Vessel Cerebrovascular Disease →
- Cadasil — all drugs for Cadasil →
- CAA - Cerebral Amyloid Angiopathy — all drugs for CAA - Cerebral Amyloid Angiopathy →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
16 and older, any sex, with Cerebral Amyloid Angiopathy or Small Vessel Cerebrovascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05734378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebral Amyloid Angiopathy
Currently open trials in the same condition.
- NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
- NCT06393712 — A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy · Phase 2 · recruiting
- NCT04204642 — SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) · recruiting
- NCT06128824 — High Frequency Imaging in Cerebral Amyloid Angiopathy · active not recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05734378 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 8 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing